Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Analysis of Mortality of Critically Ill Patients With COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04379258
Recruitment Status : Completed
First Posted : May 7, 2020
Last Update Posted : September 28, 2021
Sponsor:
Collaborators:
Hospital Universitario del Tajo
Puerta de Hierro University Hospital
Hospital de Henares
Hospital Universitario Ramon y Cajal
Hospital Universitario de Móstoles
Hospital Universitario Severo Ochoa
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Hospital Universitario Madrid Sanchinarro
Hospital Universitario Santa Creu i Sant Pau
Hospital Universitario Infanta Cristina
Hospital General Universitario Gregorio Marañon
Hospital Universitario de Torrejón
Hospital Universitario La Paz
Hospital Universitario 12 de Octubre
Hospital Christus Muguerza Betania, Puebla, Mexico
Hospital General de Mexico
Hospital Regional 1º de Octubre ISSSTE Mexico
Hospital Juarez de Mexico
Hospital Gea Gonzalez Mexico
Hospital Civil de Guadalajara, Mexico
Hospital Regional de alta Especialidad Ixta, Mexico
Hospital Ángeles Tampico, Mexico
Hospital de la Beneficiencia Espaañola, Tampico, Mexico
Hospital Ángeles Tijuana, Mexico
Hospital Universitario UANL, Mexico
Hospital H+ Querétaro, Mexico
Hospital General de Zona 1A Venados, Mexico
Centro Médico ABC Observatorio, Mexico
Hospital Christus Muguerza Alta Especialidad, Nuevo León, Mexico
Information provided by (Responsible Party):
Hospital Universitario Getafe

Brief Summary:
The recent pandemic of the COVID-19 disease has caused a national health emergency due to its severity and the clinical and social consequences of the disease. Crude mortality in Spain is 9.2%. However, the causes of death of critically ill patients with COVID-19 are unknown. To date, no treatment has been shown to be effective for the 2019-SARS-CoV-2 infection is recommended. Supportive care and isolation are recommended for infected individuals. Currently, observational studies on critically ill patients with COVID-19 have small samples. The objective is to evaluate the incidence of mortality and morbidity in COVID-19 disease in this group of critically ill patients, as well as the risk factors associated with mortality and the effectiveness of the treatments used compassionately.

Condition or disease
COVID-19 Critical Illness Effectiveness Outcome, Fatal

Show Show detailed description

Layout table for study information
Study Type : Observational [Patient Registry]
Actual Enrollment : 868 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 2 Months
Official Title: Epidemiological Analysis of the Mortality of Critically Ill Patients With the COVID-19 Admitted to the Intensive Care Unit: An Observational, Prospective and Multicenter Study
Actual Study Start Date : February 8, 2021
Actual Primary Completion Date : February 8, 2021
Actual Study Completion Date : February 8, 2021



Primary Outcome Measures :
  1. ICU mortality [ Time Frame: events during the ICU stay, up to 3 months ]
    rate (%)


Secondary Outcome Measures :
  1. hospital mortality [ Time Frame: events through study completion during the hospital stay, up to 5 months ]
    rate (%)

  2. 28-day mortality [ Time Frame: events through study completion considered from ICU admission up to 28 days ]
    rate (%)

  3. effectiveness of treatment [ Time Frame: through study completion considered from ICU admission until ICU discharge, up to 3 months ]
    rate (%). Incidence of outcome measures (ICU mortality), and appearance of complications (pneumonia or bacteriemia during ICU stay).

  4. length of ICU stay [ Time Frame: through study completion during ICU stay considered from ICU admission until ICU discharge as date of inclusion until the date of first documented discharge or date of death from any cause, whichever came first, assessed up to 3 months ]
    days

  5. length of hospital stay [ Time Frame: through study completion during ICU stay considered from ICU admission until ICU discharge as date of inclusion until the date of first documented hospital discharge or date of death from any cause, whichever came first, assessed up to 5 months ]
    days

  6. ventilator-associated pneumonia [ Time Frame: through duration of invasive ventilatory support period (from intubation date until date of successful extubation) through study completion up to 3 months ]
    rate (%)

  7. bacteriemia [ Time Frame: through study completion, up to 28-days ]
    rate (%)

  8. barotrauma [ Time Frame: through study completion, up to 28-days ]
    rate (%)

  9. duration of mechanical ventilation [ Time Frame: period of invasive controlled ventilatory support from date of orotraqueal intubation until date of successful extubation or assessed up to 3 months whichever came first ]
    days



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Case definition : Any critically ill patients with a positive respiratory tract sample result (tracheal aspirate or nasopharyngeal exudate) using the PCR9 technique for the SARS-CoV-2 virus and requiring admission to the ICU at trial will be considered a confirmed case of COVID-19 disease of the doctor responsible for the sick.
Criteria

Inclusion Criteria:

  • patients over 18 years of age who are admitted to the ICU with the confirmed diagnosis of COVID-19.

Exclusion Criteria:

  • none

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04379258


Locations
Layout table for location information
Spain
Hospital Universitario de Getafe
Getafe, Madrid, Spain, 28905
Sponsors and Collaborators
Hospital Universitario Getafe
Hospital Universitario del Tajo
Puerta de Hierro University Hospital
Hospital de Henares
Hospital Universitario Ramon y Cajal
Hospital Universitario de Móstoles
Hospital Universitario Severo Ochoa
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Hospital Universitario Madrid Sanchinarro
Hospital Universitario Santa Creu i Sant Pau
Hospital Universitario Infanta Cristina
Hospital General Universitario Gregorio Marañon
Hospital Universitario de Torrejón
Hospital Universitario La Paz
Hospital Universitario 12 de Octubre
Hospital Christus Muguerza Betania, Puebla, Mexico
Hospital General de Mexico
Hospital Regional 1º de Octubre ISSSTE Mexico
Hospital Juarez de Mexico
Hospital Gea Gonzalez Mexico
Hospital Civil de Guadalajara, Mexico
Hospital Regional de alta Especialidad Ixta, Mexico
Hospital Ángeles Tampico, Mexico
Hospital de la Beneficiencia Espaañola, Tampico, Mexico
Hospital Ángeles Tijuana, Mexico
Hospital Universitario UANL, Mexico
Hospital H+ Querétaro, Mexico
Hospital General de Zona 1A Venados, Mexico
Centro Médico ABC Observatorio, Mexico
Hospital Christus Muguerza Alta Especialidad, Nuevo León, Mexico
Investigators
Layout table for investigator information
Principal Investigator: Oscar Peñuelas, P.h.D Fundación de Investigación del Hospital Universitario de Getafe
Publications of Results:
Other Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Hospital Universitario Getafe
ClinicalTrials.gov Identifier: NCT04379258    
Other Study ID Numbers: COVID-UCI_Spain
First Posted: May 7, 2020    Key Record Dates
Last Update Posted: September 28, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: study protocol
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: 3 months
Access Criteria: Direct request to the Principal Investigator

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Critical Illness
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Disease Attributes
Pathologic Processes